Reckitt Benckiser Group plc (LON:RKT - Get Free Report)'s stock price rose 2.2% during trading on Friday . The company traded as high as GBX 4,868 ($61.03) and last traded at GBX 4,847 ($60.76). Approximately 1,886,302 shares changed hands during mid-day trading, a decline of 41% from the average daily volume of 3,203,260 shares. The stock had previously closed at GBX 4,741 ($59.43).
A number of research firms recently weighed in on RKT. Jefferies Financial Group reaffirmed a "hold" rating and issued a GBX 4,400 ($55.16) price objective on shares of Reckitt Benckiser Group in a research note on Monday, July 29th. Berenberg Bank decreased their price objective on Reckitt Benckiser Group from GBX 5,200 ($65.19) to GBX 5,177 ($64.90) and set a "hold" rating for the company in a report on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. lowered Reckitt Benckiser Group to a "neutral" rating in a report on Friday, August 30th.
Read Our Latest Research Report on RKT
The company has a market cap of £33.50 billion, a P/E ratio of 2,233.64, a price-to-earnings-growth ratio of 1.10 and a beta of 0.09. The company has a quick ratio of 0.46, a current ratio of 0.69 and a debt-to-equity ratio of 112.52. The firm's 50-day moving average price is GBX 4,714.96 and its 200-day moving average price is GBX 4,495.09.
In other news, insider Fiona Dawson acquired 25 shares of Reckitt Benckiser Group stock in a transaction that occurred on Wednesday, October 23rd. The stock was bought at an average price of GBX 4,923 ($61.71) per share, with a total value of £1,230.75 ($1,542.87). Insiders own 0.05% of the company's stock.
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.